Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetShares Issued
Ratios

TriSalus Life Sciences (TLSIW) Accumulated Depreciation & Amortization (2022 - 2025)

TriSalus Life Sciences' Accumulated Depreciation & Amortization history spans 4 years, with the latest figure at $626000.0 for Q4 2025.

  • For Q4 2025, Accumulated Depreciation & Amortization fell 15.86% year-over-year to $626000.0; the TTM value through Dec 2025 reached $626000.0, down 15.86%, while the annual FY2025 figure was $626000.0, 15.86% down from the prior year.
  • Accumulated Depreciation & Amortization reached $626000.0 in Q4 2025 per TLSIW's latest filing, up from $500000.0 in the prior quarter.
  • In the past five years, Accumulated Depreciation & Amortization ranged from a high of $744000.0 in Q4 2024 to a low of $172000.0 in Q1 2025.
  • Average Accumulated Depreciation & Amortization over 4 years is $455600.0, with a median of $449000.0 recorded in 2022.
  • Peak YoY movement for Accumulated Depreciation & Amortization: skyrocketed 71.86% in 2023, then dropped 15.86% in 2025.
  • A 4-year view of Accumulated Depreciation & Amortization shows it stood at $398000.0 in 2022, then soared by 71.86% to $684000.0 in 2023, then grew by 8.77% to $744000.0 in 2024, then fell by 15.86% to $626000.0 in 2025.
  • Per Business Quant, the three most recent readings for TLSIW's Accumulated Depreciation & Amortization are $626000.0 (Q4 2025), $500000.0 (Q3 2025), and $337000.0 (Q2 2025).